celltrion’s Infliximab SC Demonstrates Consistent Crohn’s Disease Efficacy Across Inflammation Sites, Post-Hoc Analysis Reveals
Seoul, South Korea – A post-hoc analysis of Phase 3 clinical trial data indicates Celltrion‘s infliximab subcutaneous (SC) maintenance treatment, marketed as Zympentra, shows significant and consistent therapeutic effects in Crohn’s disease patients regardless of inflammation location.The findings, stemming from the LIBERTY-CD trial involving 343 patients – with 102 receiving Zympentra – differentiate the treatment from existing Crohn’s therapies that frequently enough exhibit varying efficacy depending on whether inflammation is present in the small intestine (ileum), colon, or rectum.
The analysis confirms a significant treatment effect compared to placebo after one year of treatment,irrespective of the site of inflammation. Celltrion officials state the results suggest Zympentra may overcome limitations of current treatments by providing consistent relief. The data also suggest the treatment’s effectiveness is unaffected by patient factors like disease duration or prior treatment resistance, and remains stable whether used as monotherapy or in combination with immunosuppressants.
“The results of this post-hoc analysis suggest the possibility of Zympentra overcoming the limitations of existing treatments by showing consistent therapeutic effects regardless of the site of inflammation,” a Celltrion official stated. “we will do our best to improve the quality of life of more patients and quickly expand prescriptions based on the already proven convenience of administration and excellent treatment effect.”
The LIBERTY-CD trial evaluated the safety and efficacy of Zympentra over 52 weeks.
